Posted by AGORACOM-JC
at 6:05 PM on Friday, May 15th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More
People are choosing cannabis over cocktails because it’s healthier
What’s a safer, healthier option to alcohol? That would be cannabis, say 90 per cent of Americans asked about their use of substances last year.
The findings seem to reflect that people trying to adopt healthier lifestyles are thinking cannabis could be a better fit than alcohol, suggests an article by Merry Jane.
A healthier lifestyle was among four factors associated with more people consuming weed in 2019 than in 2018. The other three factors include there being less stigma around cannabis, legalization and decriminalization efforts, and pot from legal U.S. states being sold on the black market in states where cannabis is still a no-no.
The National Cannabis Study, released last month by marketing research firm MRI-Simmons, notes the single-year jump in cannabis consumption between 2018 and 2019 was significant. About 22 per cent of surveyed Americans consumed weed at least once in 2019 compared to 16 per cent in 2018. That represents a 38 per cent hike.
Of those who used cannabis in 2019, the survey shows 17 per cent consumed once a month or more, while seven per cent consumed daily.
Cannabis, herbal supplements and vitamins were all up from 2018 to 2019. / Photo: Christopher Furlong/Getty Images Christopher Furlong/Getty Images
While consumption of cannabis, herbal supplements and vitamins were all up from 2018 to 2019, caffeine and alcohol consumption dropped slightly, both by about three per cent.
About 58 per cent of respondents also said that marijuana should be legal, up from 56 per cent in 2018, and almost two-thirds, 64 per cent, over the age of 18 expect marijuana to become legalized in all states within the next five years.
The study used a nationally representative online sample of more than 5,000 respondents.
Posted by AGORACOM-JC
at 9:27 PM on Wednesday, May 13th, 2020
“As the country begins to emerge from stay at home orders, we thought it would be prudent to provide our shareholders with an update on our operations and some additional details on our recently announced acquisitions, Alphamind and Venom Extracts.” Said Carl Saling, CEO Hollister. “Integration of the new companies is well underway and continues to run smoothly”
VANCOUVER, May 13, 2020 - Hollister Biosciences Inc. (CSE: HOLL, OTC: HSTRF, FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to provide a Corporate Update from CEO, Carl Saling.
“As the country begins to emerge from stay at home orders, we thought it would be prudent to provide our shareholders with an update on our operations and some additional details on our recently announced acquisitions, Alphamind and Venom Extracts.” Said Carl Saling, CEO Hollister. “Integration of the new companies is well underway and continues to run smoothly”
COVID-19 (the “Pandemic”) Update
In many states across the country cannabis was deemed an essential business and Hollister has been able to stay operational in all the states in which it operates.
It has been a challenging environment; however, we have navigated the new environment effectively. Some cities and counties only allowed curbside pick-up and or delivery of cannabis, while others have closed but others stayed completely open for business using and implementing safety precautions.
Hollister took action to help the communities in which they operate by manufacturing hand sanitizer and donated it to offices and front-line workers. As recognition for our efforts the county of Hollister, California awarded Hollister Cannabis Co. a Certificate of Appreciation for our support.
Today, Hollister’s facilities are operating under social distancing guidelines to ensure the Company’s employees are safe. The Company has also provided employees with gloves, masks and hand sanitizer to take home. It is the Company’s first order concern during the pandemic to ensure that employees are operating in a safe and healthy environment and provide them with the tools they need to keep themselves and their families safe.
Hollister Cannabis Co.
Hashbone, the Company’s bubble hash infused pre roll brand, continues to grow and gain new fans daily. The Company introduced HashBone “Minis” which are 0.5 gram bubble hash infused pre-rolls packaged in a 5 pack. The Company has rolled out Hybrid and Sativa SKU’s now available in select California dispensaries.
The Company also plans to introduce the HashBone “Wolfie”, which answers the call of the true connoisseur. The HashBone Wolfie is a traditional HashBone coated with full spectrum cannabis oil and rolled in bubble hash. There is hash on the inside and hash on the outside with full spectrum oil holding them together. The HashBone Wolfie is currently in the testing phase and estimated to be in the market before the end of May 2020.
Strategic Alliances with Tommy Chong
Further to the news release dated February 7, 2020, the Company is pleased to disclose the strategic relationship with Tommy Chong is progressing well. Hollister is very close to launching its 1st SKU with Tommy Chong called Tommy Chong’s Cannabis Full Spectrum Elixir comprising a 1:1 ratio – 500mg CBD: 500mg THC. The product has completed testing, labels are being generated, and the Company expects product launch before the end of May 2020.
Venom Extracts
Venom Extracts (“Venom“) continues to be integrated within Hollister Biosciences operations and the synergies are evident. Plans are underway for expansion of Venom into Hollister’s manufacturing facility in California with engineering and permitting processes underway. The Company anticipates Venom will be producing in California in Q4 2020.
Throughout the pandemic, Venom products continued to see significant growth in demand which resulted in record revenue for Q1, 2020. Although these numbers will be disclosed in Hollister’s Q1 report, only a small portion will be included in Hollister’s audited financial statements, as the acquisition closed on March 24, 2020
AlphaMind
The integration process is underway pursuant to the Company’s recently announced acquisition of AlphaMind (see News release dated April 30, 2020). The Company believes AlphaMind’s medicinal mushroom based product SKU’s will be complementary to Hollister’s existing product line. AlphaMind has an agreement in place with an established US based manufacturing partner. It is the Company’s intention to build out an e-commerce platform to market and distribute AlphaMind’s product line. AlphaMind is a new entrant in the burgeoning medicinal mushroom sector and is also in the process of developing IP surrounding psilocybin based pharmaceutical treatments.
Future Objectives
The Company believes the pandemic has changed consumer behaviour, possibly in a permanent fashion.
Hollister believes it can capitalize on this in several ways:
The company is looking to accelerate its direct to consumer platform for both the hemp and the cannabis markets.
Hollister Biosciences will look to build a centralized ecommerce management system that will streamline the sales and marketing of all Hollister Biosciences non cannabis brands like Rebel Hemp Company & AlphaMind.
The Company will continue to evaluate the changing cannabis regulatory landscape to expand operations into new states.
The Company will also evaluate new technologies which may be utilized in the Company’s Facilities in the future.
Hollister Cannabis Co. is currently in the design phase of expanding its facility to accommodate the Venom brand.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Tags: Cannabis, CBD, CSE, Hemp, small cap, tsx Posted in Hollister Biosciences | Comments Off on Hollister Biosciences Inc. $HOLL.ca CEO Provides Corporate Update $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Vision is to capitalize on this success to become the sought after premium brand portfolio of Cannabis across multiple states and Hemp nationwide
Major LOI, Joint Ventures and Licensing Agreements Support Proof Of This Vision
“Easy Riders” – Milliions Of Global Followers
“Tactical Relief” – Veteran Founded, Hemp Based CBD Brand With Nation Wide Members
“Tommy Chong” – Exclusive Manufacture & Distribution Of Tommy Chong’s Cannabis (TM) Full Spectrum Elixir 1:1
“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”.
one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.
HIGHLY ACCRETIVE $20,000,000 ACQUISITION, ADDING OVER CDN$16.4 MILLION OF 2019 REVENUE
For the year ended December 31, 2019, management of Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million in EBITDA from its product line of cannabis concentrates and cartridges.Â
Venom Extract’s management also reports a strong start to 2020 and is anticipating record Q1 revenue.
Alphamind Brands is developing a portfolio of certified legal mushroom based natural health products
The company’s “ready to ship†product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.
FULL DISCLOSURE: Hollister Biosciences Inc. is an advertising client of AGORA Internet Relations Corp.
Posted by AGORACOM-JC
at 9:45 PM on Sunday, May 10th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More
How The Cannabis Industry Is Coping In 2020
Canada and most U.S. states with legalized cannabis industries declared dispensaries as essential services, allowing sales to continue throughout the COVID-19 crisis, enabling robust demand to be met
Even with strong sales momentum, cannabis stocks broadly suffered during the quarter amid heightened market volatility
Early-stage cannabis companies rely heavily on external capital to fuel their growth ambitions, but investors are stepping back from financing riskier industries in the current environment
Despite these near-term challenges, we remain optimistic on the longer-term prospects for cannabis as its acceptance grows
Amid widespread COVID-19-related retail store closures, many cannabis dispensaries received “essential business” designations. This allowed cannabis consumers to stock up on medicinal and recreational cannabis, fueling strong sales figures despite a tumultuous Q1 2020. Yet, even with strong sales momentum, cannabis stocks broadly suffered during the quarter amid heightened market volatility. Early-stage cannabis companies rely heavily on external capital to fuel their growth ambitions, but investors are stepping back from financing riskier industries in the current environment. Some cannabis companies are now running low on cash, forcing them to sell stakes at undesirable valuations or scale back operations or staffing.
Despite these near-term challenges, we remain optimistic on the longer-term prospects for cannabis as its acceptance grows. New store openings and the sale of edibles are helping to fuel greater legal consumption. In addition, COVID-19’s economic impact is broadly hurting tax revenues at the local, state, and federal level, potentially providing greater impetus to legalize and tax cannabis. With only about 10% of cannabis sales occurring through legal channels, we believe there is substantial opportunity for continued growth across regulated channels.
Is Cannabis A Consumer Staple?
The COVID-19 crisis is plunging the global economy into recession, yet its impact will not be felt equally across industries. During recessions, consumers may forgo discretionary items like jewelry or electronics, but staples such as essential food and beverages tend to see robust sales. Historically, alcohol and tobacco exhibit staples-like characteristics, demonstrating strong sales despite economic weakness. During the global financial crisis, for example, alcohol consumption increased 7.2% in 2008-09 from 2006-07 levels, while total sales in the consumer discretionary sector fell by -9.35% over that time frame.1,2
Legalized cannabis did not exist during the Great Recession, but recent figures suggest cannabis sales share similar characteristics with alcohol and tobacco. Canada and most U.S. states with legalized cannabis industries declared dispensaries as essential services, allowing sales to continue throughout the COVID-19 crisis, enabling robust demand to be met.
Online cannabis purchases in Ontario have surged from 5,000 orders in mid-March to 9,000 orders by mid-April.3
Oregon’s cannabis sales increased 37% year over year in March, its highest single-month increase.4
Between March 16th and March 22nd, year-over-year sales of recreational cannabis across key US markets, including California, Colorado, Oregon and Alaska, were up 50%.5
One of Nevada’s largest cannabis delivery businesses reported a 400% increase in cannabis retail deliveries since March 20th.6
While lockdown may have accelerated cannabis demand, cannabis sales were already on an accelerating path. January and February sales numbers in Canada increased 181% year-over-year to C$154 million and 190% to C$150 million.7 Estimates from Cannabis Benchmarks for March sales show a spike to C$216 million, more than three times March 2019’s sales of C$59 million.8
The shift towards greater cannabis acceptance has spurred much of this growth. Cannabis consumers among the legal adult population in Canada grew to 63% at the end of 2019 from 54% in 2018.9
Canada’s new recreational cannabis market, dubbed Rec 2.0, is also fueling growth. Rec 2.0 officially launched at the end of 2019, almost a year after legalization in Canada. Before Rec 2.0, only dried flower and oil were products sold, but now the sale of cannabis beverages, edibles and vapes, among other forms, is permitted. Derivative formats like these account for almost half of sales in mature and developed markets such as Colorado, showing how Rec 2.0 could play a major role in accelerating cannabis sales in Canada. Aurora Cannabis (ACB), for example, recently mentioned that approximately 20% of total sales could come from Rec 2.0 products.10 OrganiGram Holdings (OGI) also reported new Rec 2.0 products to account for 13% of total revenue in its most recent quarter.11
New Store Openings Grow Legal Cannabis’s Market Share
Curbing illicit cannabis sales is on the agenda for many governments around the world. Globally, legal cannabis sales reached $15 billion at the end of 2019, which is less than 10% of the estimated total market of $160 billion.12 Such low penetration both demonstrates the growth opportunity ahead as well as highlights some of the challenges for the legal market. In Canada, for instance, limited dispensary licenses plays a major factor, as recreational cannabis sales per capita are highly correlated to the number of stores.
In Q1 2020, Canada opened 191 new stores, bringing its total to 806.13 Ontario, Canada’s most populous province, now has 52 stores, versus just 27 at the end of 2019. But the few dozen stores represent just four per 1 million people. For comparison, Colorado has 180 stores for every 1 million people.14 The store comparison between the two countries is notable, as further licenses should help meet consumer demand and promote greater legal sales.
Within the U.S., active dispensary licenses are up 5.5% year-to-date, with 385 new stores opening around the country.15 Yet, given that the US has nine times more dispensary licenses than Canada, more stores is a less critical factor than wider legalization across populous states or at the broader federal level.
Cannabis Industry Leveraging E-commerce To Further Grow Sales
Oftentimes, crises breed both new problems and new solutions. During this social distancing era, Colorado legalized online sales of recreational cannabis, fulfilling a longstanding request from cannabis companies.16 Cannabis consumers can now order, pay online and pick up at-store. A few other states – Massachusetts, Illinois, Michigan and Oregon – already allow cannabis e-commerce.
In Canada, the Alcohol and Gaming Commission of Ontario (AGCO) authorized cannabis retail stores to offer e-commerce solutions, starting April 7th.17 E-commerce authorization resulted from an emergency order by the Government of Ontario to deter illegal cannabis sales amid physical distance mandates. For now, the measure is temporary, but it includes the possibility of extension.
Financing Cannabis’s Growth
Early-stage industries tend to rely on the capital markets to fund growth. The phenomenon describes a healthy dynamic between those with capital to invest and those seeking capital for growth. The cannabis industry is particularly dependent on capital, as growing, harvesting, packaging and distribution require property, equipment and employees. With high growth expectations, cannabis companies tend to plow their freshly raised capital into various parts of the ecosystem, leaving little cash available to weather a storm. The constant need for new financing can expose weaker companies that may need to raise capital at undesirable terms, or worse, cannot raise additional capital at all.
HEXO Corp. (HEXO), for example, a leading cannabis grower in Canada, recently closed a C$46 million public offering but was forced to sell its equity 20% below its last traded price.18 Other larger players have followed suit, like Tilray (TLRY), which raised C$90 also at a 20% discount.19
There are companies, however, with strong cash positions that may be able to weather this challenging financing environment better than others. Canopy Growth Corp. (CGC) and Cronos Group (CRON) both have over $1 billion in cash & equivalents on their balance sheets. GW Pharmaceuticals (GWPH) holds over $500 million in cash & equivalents. Balance sheet strength allows these companies to potentially wait longer before needing to raise additional outside capital.
COVID-19 Could Expedite Cannabis Legalization
In our article “Themes for Defensive Positioning,” we highlighted that economic downturns can accelerate efforts to find new sources of economic stimulus and tax revenue. Legalizing (and taxing) recreational cannabis is one such avenue states could pursue given its track record of generating economic growth and taxes. Estimates hold that nationwide legalization in the U.S. could generate $132 billion in aggregate tax revenue and more than a million new jobs across the country by 2025.20 Such growth comes not from an unproven, speculative market, but from the conversion of a largely illicit market to a legal, regulated one. Such taxes and economic growth could be particularly welcome given stalling economic growth and swelling debt caused by COVID-19.
This year, several states could legalize recreational use. Virginia recently decriminalized cannabis, joining 27 other states that have taken such actions.21 The bill doesn’t legalize cannabis sales yet, but Virginia’s Governor is also clearing the path for easier access for medicinal uses.22 In New Jersey, lawmakers voted to add legalization to November’s ballot. Should the bill pass, it could add additional pressure to neighboring New York and Connecticut.
Illinois, where legalized cannabis went into effect in January, is the most recent model other states could follow. Illinois has the second-highest tax regime on cannabis sales in the country, where taxes vary from 10% to 25%.23 In Q1, Illinois cannabis stores sold $110 million, generating at least $11 million in tax revenues. Another benchmark is Colorado, which legalized cannabis in 2014. In Q1 2020, Colorado generated $79 million in tax revenue from cannabis-related sales.24 In 2019 alone, the state collected over $300 million in tax revenue, which was earmarked for cannabis regulation, research and schools.25
With a global recession looming, the economic benefits of legalized cannabis could be too enticing for states, provinces and countries to ignore.
Conclusion
The recent increase in cannabis sales in the U.S. and Canada since COVID-19 reflects the non-cyclical nature of cannabis sales. While some cannabis companies may struggle from lack of access to capital during this volatile period, the stronger ones could continue to see substantial growth as they meet robust consumer demand. Trends in new dispensary openings, a shift to e-commerce, and the introduction of new consumable forms of cannabis should further fuel growth across North America. Longer term, the potential for further legalization efforts amid the COVID-19 crisis should provide a tailwind to the industry.
Related ETFs
POTX: The Global X Cannabis ETF seeks to invest in companies across the cannabis industry. This includes companies involved in the legal production, growth and distribution of cannabis and industrial hemp, as well as those involved in providing financial services to the cannabis industry, pharmaceutical applications of cannabis, cannabidiol (i.e., CBD), or other related uses including but not limited to extracts, derivatives or synthetic versions.
Please click on the fund name for current holdings.
Footnotes
1. Jacob Bor, et al. “Alcohol Use During the Great Recession of 2008-2009,” January 29, 2013.
2. U.S. Census Bureau. Discretionary sales including retail sales of Motor Vehicles & Parts, Furnitures, Electronics & Appliances, Clothing, Sporting Goods, General Merchandise, and Miscellaneous Stores. Accessed on April 2020.
3. Cannabis Benchmarks, “Canada Cannabis Spot Index (CCSI)”, April 17, 2020.
4. Willamette Week, “Oregon Cannabis Sales in March Were the Highest Ever for a Single Month,” April 6, 2020.
5. New York Post, “Cannabis sales hit new highs in US and Canada,” March 24, 2020
6. Reno Gazette Journal, “Nevada marijuana deliveries are skyrocketing. Is this the new normal for the pot industry?,” March 30, 2020.
7. Statistics Canada, “Cannabis Stores Sales,” Accessed on April 2020.
8. Cannabis Benchmarks, (n3).
9. BDS Analytics, “How Will “Cannabis 2.0″ Affect the Legal Canadian Market?,” February 18, 2020.
16. The Colorado Sun, “Coronavirus fuels marijuana industry’s push for online sales, delivery in Colorado,” April 13, 2020.
17. Alcohol and Gaming Commission of Ontario, “Ontario Allows Cannabis Delivery and Curbside Pick-up from Authorized Retail Stores During COVID-19,” April 7, 2020.
18. Hexo Corp, “HEXO Corp. Closes $46 Million Underwritten Public Offering,” April 13, 2020.
19. Tilray, “Tilray, Inc. Announces Pricing of its $90.4 Million Registered Offering,” March 13, 2020.
20. The Washington Post, “Study: Legal marijuana could generate more than $132 billion in federal tax revenue and 1 million jobs,” January 10, 2018.
21. Leafly, “Virginia just decriminalized marijuana. Here’s what that means,” April 13, 2020.
22. Marijuana Moment, “Virginia Governor Urges Medical Marijuana Expansion As Amendment To Recently Approved Bill,” April 15, 2020.
23. Illinois Policy, “What you need to know about marijuana legalization in Illinois?,” January 1, 2020.
24. Colorado Department of Revenue, “Marijuana Tax Data,” April 2020.
25. Ibis.
Investing involves risk, including the possible loss of principal. The investable universe of companies in which POTX may invest may be limited. The Fund invests in securities of companies engaged in Healthcare and Pharmaceutical sectors. These sectors can be affected by government regulations, expiring patents, rapid product obsolescence, and intense industry competition. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. POTX is non-diversified.
POTX’s investments are concentrated in the cannabis industry, and the Fund may be susceptible to loss due to adverse occurrences affecting this industry. The cannabis industry is a very young, fast evolving industry with increased exposure to the risks associated with changes in applicable laws (including increased regulation, other rule changes, and related federal and state enforcement activities), as well as market developments, which may cause businesses to contract or close suddenly and negatively impact the value of securities held by the Fund. Cannabis Companies are subject to various laws and regulations that may differ at the state/local, federal and international level. These laws and regulations may significantly affect a Cannabis Company’s ability to secure financing and traditional banking services, impact the market for cannabis business sales and services, and set limitations on cannabis use, production, transportation, export and storage. The possession, use and importation of marijuana remains illegal under U.S. federal law. Federal law criminalizing the use of marijuana remains enforceable notwithstanding state laws that legalize its use for medicinal and recreational purposes. This conflict creates volatility and risk for all Cannabis Companies, and any stepped-up enforcement of marijuana laws by the federal government could adversely affect the value of the Fund’s investments. Given the uncertain nature of the regulation of the cannabis industry in the United States, the Fund’s investment in certain entities could, under unique circumstances, raise issues under one or more of those laws, and any investigation or prosecution related to those investments could result in expense and losses to the Fund.
Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. The closing price is the Mid-Point between the Bid and Ask price as of the close of exchange. Closing price returns do not represent the returns you would receive if you traded shares at other times. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.
Since the Fund’s shares did not trade in the secondary market until several days after the Fund’s inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.
Global X Management Company LLC serves as an advisor to Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO), which is not affiliated with Global X Management Company LLC or Mirae Asset Global Investments. Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.
Tags: Cannabis, CBD, CSE, Hemp, small cap, tsx, tsx-v, weed Posted in Hollister Biosciences | Comments Off on How The #Cannabis Industry Is Coping In 2020 – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 9:00 PM on Sunday, May 3rd, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More
Israel Researchers Launch Clinical Trials To Test CBD As COVID-19 Treatment Supplement
Israeli researchers have launched three clinical trials that utilize CBD’s anti-inflammatory properties as potential COVID-19 treatment.
Israeli scientists have launched clinical trials into whether cannabis can play an effective role in stopping or slowing the coronavirus
Though lung health experts have warned smoking marijuana could exacerbate COVID-19 and its spread, Israeli scientists will study cannabidiol (CBD) alongside existing treatment options as a possible solution
Israeli scientists have launched clinical trials into whether cannabis can play an effective role in stopping or slowing the coronavirus. Though lung health experts have warned smoking marijuana could exacerbate COVID-19 and its spread, Israeli scientists will study cannabidiol (CBD) alongside existing treatment options as a possible solution.
Last week, InnoCan Pharma announced a collaboration with Tel Aviv University to instill CBD medicine through exosomes — or the small cell structures created when stem cells multiply. The unconventional method will utilize the exosomes as “homing missiles,†as they can uniquely target cell organs damaged by COVID-19. Researchers then believe CBD’s anti-inflammatory properties will repair the damaged cells through a synergistic effect. As COVID-19 attacks the respiratory system, scientists will have patients receive CBD-enriched exosomes through an inhalation device. Previous studies have shown CBD can help regulate the body’s immune system and reduce inflammation throughout the body.
A second clinical trial will occur over the coming weeks and includes 10 Covid-19 patients currently undergoing treatment in Israel’s Rabin Medical Center. Doctors will combine traditional steroids and CBD, with the belief CBD will enhance the therapeutic potential of the steroids. The trial, conducted by Stero Biotechs in collaboration with Mor Research Application, already has plans to expand treatment to 40 additional patients should it prove successful.
“We estimate that our CBD-based treatment can enhance the current treatment of those patients who are in life-threatening conditions,†Stero Biotechs founder and CEO David Bassa said in a statement. “Hospitalized COVID-19 patients are mostly being treated with steroids and our study is planned to demonstrate the benefit of a combined solution with Steroid treatments. We are hopeful that this study will lead to faster benefit for the growing number of COVID-19 patients in Israel and around the world.â€
A third study, launched by Tel Aviv’s Ichilov Medical Center, will investigate whether CBD’s anti-inflammatory properties could lower respiratory symptoms experienced in moderate COVID-19 patients.
Canadian researchers have also announced intentions to study what role cannabis can play in slowing COVID-19. They also believe marijuana’s anti-inflammatory properties could provide a crucial role in potential treatment.
Posted by AGORACOM-JC
at 8:15 AM on Thursday, April 30th, 2020
Company has now closed its acquisition of AlphaMind Brands Inc., a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products
Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction
VANCOUVER, April 30, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that further to the signing of the definitive agreement, as amended (the “SEA“), the Company has now closed its acquisition of AlphaMind Brands Inc. (“AlphaMind“), a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products (the “Transaction“).
“We are very pleased to close our acquisition of AlphaMind”, shared Carl Saling, Founder and CEO of Hollister. “It is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering. We are excited to bring another promising brand under the Hollister umbrella, especially in such a fast growing and exciting sector.”
“We are very pleased to have closed this transaction”, shared Dr. Nikos C. Apostolopoulos, Chief Product & Research Officer of Alphamind Brands. “We are looking forward to working with Hollister to build out our medicinal mushroom based product line and conducting further R&D to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments.”
Key Terms of The Transaction
Pursuant to the terms of the SEA, the Company has acquired AlphaMind for consideration of CDN$1,200,000 which is being satisfied by the issuance of 4,200,000 Hollister common shares (the “Payment Shares“) on the Closing Date pro rata to the shareholders of AlphaMind and an additional 1,800,000 common shares (the “Earn-Out Shares“) to be issued pro rata to the former shareholders of AlphaMind on the earlier of (i) AlphaMind meeting certain milestones (detailed below) or (ii) December 31st, 2021.
The Payment Shares and the Earn-Out Shares will be issued at a deemed value of $0.20 per share;
The Payment Shares are subject to certain voluntary hold periods as follows: 331/3% until May 30th, 2020; an additional 331/3% until June 30th, 2020; and the remaining 331/3% until August 30th, 2020;
The Earn-Out Shares will be issued on the earlier of (i) December 31st, 2020, or (ii) upon AlphaMind’s first production run or its first sales of product.
Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction.
About AlphaMind Brands Inc.
Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments. The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
The CSE has not in any way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.
The securities to be issued in connection with the Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Posted by AGORACOM-JC
at 8:20 AM on Thursday, April 23rd, 2020
Entered into a share exchange agreement dated April 22nd, 2020 among the Company, AlphaMind Brands Inc. and the shareholders of TargetCo
Alphamind Brands is developing a portfolio of certified legal mushroom based natural health products
The company’s “ready to ship†product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.
VANCOUVER, April 23, 2020 –Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that it has entered into a share exchange agreement dated April 22nd, 2020 among the Company, AlphaMind Brands Inc. (“TargetCo“) and the shareholders of TargetCo (the “Definitive Agreement“), pursuant to which, the Company will acquire all of the issued and outstanding shares of TargetCo (the “Proposed Transaction“). Â
Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments. The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.
“We are very pleased to have completed the next step in consummating this very exciting acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences, Inc. “It is a fundamental value of our company to improve the overall health and performance of our customers through our high-quality products and the health benefits associated with medicinal mushrooms are tremendous. Not to mention, it is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.”
“I think we have found a great partner in Hollister”, shared Robert Birmingham, CEO of Alphamind Brands. “We have medicinal mushroom based product SKU’s ready to ship and R&D is underway to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments. Being under the Hollister umbrella will allow us to access additional markets and leverage their existing manufacturing and distribution infrastructure and will be a fundamental part of the future growth of our business.”
The Proposed Transaction
Pursuant to the terms of the Definitive Agreement, Hollister will acquire all of the issued and outstanding securities of TargetCo in consideration for the issuance of 6,000,000 common shares of the Company (the “Payment Shares“) pro rata to shareholders of TargetCo at a deemed price of $0.20 per Payment Share upon closing of the Proposed Transaction (the “Closing Date“).
The Proposed Transaction remains subject to certain closing conditions including, without limitation, (a) the receipt by Hollister of any necessary corporate and regulatory approval; and (b) each party’s representations and warranties in the Definitive Agreement being true and correct in all aspects as of the Closing Date, and each party meeting its terms and conditions and completing its covenants and obligations as contained therein. There can be no guarantees that the Proposed Transaction will be completed as contemplated or at all.
Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Proposed Transaction.
In addition, the Company also reports that it will issue 500,000 common shares at a deemed price of $0.12 per share to an arm’s length consultant pursuant to a consulting agreement in which services were provided from December 1, 2019 to the date hereof. In addition, the Company will issue 90,400 shares to an arm’s length consultant pursuant to a consulting agreement in which services have been rendered since February 17, 2020 (See press release dated February 25th, 2020). All shares issued pursuant to the consulting agreements will be subject to a four month and a day hold period from the date of issuance.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
The CSE has not in any way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.
The securities to be issued in connection with the Proposed Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Posted by AGORACOM-JC
at 7:20 AM on Monday, April 20th, 2020
Through its Hollister Cannabis Co division, has become an official brand partner of Farechild Events’ Chronic Relief 4/20 fundraiser.
Virtual event has been established to help the Feeding America network of food banks as they support communities and families impacted by the COVID-19 pandemic.
Hollister Biosciences Inc., the creator of California’s #1 hash-infused pre-roll HashBone, joins a global group of cannabis’ biggest stars for an unprecedented live web broadcast on one of the world’s “highest” holidays to feed hungry families during the global coronavirus pandemic. Â
VANCOUVER, April 20, 2020Â –Hollister Biosciences Inc.(CSE: HOLL, OTC: HSTRF, FRANKFURT: HOB) (the “Company” or “Hollister“) – through its Hollister Cannabis Co division, has become an official brand partner of Farechild Events’ Chronic Relief 4/20 fundraiser.Â
An extraordinary line-up of game-changing cannabis personalities, activists, actors, musicians, athletes, journalists and brands have banded together for Chronic Relief – a ground-breaking free telethon live-web broadcast, with 100% of all funds raised via donation given to Feeding America COVID-19 Response Fund (501c3). This virtual event has been established to help the Feeding America network of food banks as they support communities and families impacted by the COVID-19 pandemic. Households facing hunger may be more susceptible to the virus, further contributing to the demands placed on food banks. Your donation will enable food banks to serve the most vulnerable members of the community and our neighbors in need, during this difficult time.
Uniting the global cannabis community in celebration of 4/20 by bringing entertainment, words of encouragement, and the giving spirit to those in need; famed cannabis event producers Dave Tran and James Zachodni of Farechild Events, Seattle-based Atomic Studios, lifestyle brand/canna-marketing company Dab Star and award-winning branding agency Wick & Mortar, along with others, come together to support those facing hunger as a result of COVID-19.
The cannabis community has embraced Chronic Relief en masse by supporting the upcoming event through a wide array of platforms in an effort to ignite passion in the American people showing that cannabis cares and is here to feed your body and mind. Brands and companies who have offered to support include: Sensi Magazine, Marijuana Venture Magazine, Cannabis Club TV, Cannabis Talk 101, PufCreativ, Enlighten, Cannabis & Tech Today, Pot Brothers At Law, Cannacon, Cannabis Now Magazine, Happy Munkey, Leaf Magazine, Haze Radio, Revel, Hempfest, Dab Tabs, Futurola, 420 Games, NECann, Respect My Region, Cannabis Alliance, Daily Leaf, Sound Cultivation, LA Cannabis News, Dip Devices, My Cannabis Accountant, Scynce LED, and Chapter 2.
“We’re at the threshold of an extreme moment of need in our human existence,” said Dave Tran, organizer of the event and one of the executive producers of the Chronic Relief broadcast. “There’s countless families who are surviving this crisis hungry, scared and unsupported. We have the network, we have the passion, we have the technology to raise awareness. Most importantly Feed America needs the funding to do their incredible work during this crisis. The support we’ve received from the cannabis media and industry community is remarkable. James and I’s phones are blowing up with everyone asking, ‘What can I do and how can I help?’ We hope our viewers all over the country will do the same on 4/20.”
Farechild Events further shared about this event: “In our current state of uncertainty, we know it’s essential to unite as a community to offer strength and optimism during this international crisis. The cannabis industry was built on the giving spirit and if there has ever been a time to harness the strength of the cannabis community, it’s now. Let’s come together to support those facing hunger as a result of the COVID-19.
We have the opportunity to make this 4/20 the most iconic celebration in our community’s history. There is no better time than the present for the cannabis space to make a lasting impact where it matters most. As all major 4/20 celebrations have been cancelled, we have the opportunity to leverage our partnerships and vast network of supporters to capture a large audience of virtual cannabis enthusiasts in support of a virtuous cause. Cannabis consumers and advocates are looking for a way to connect with their peers on 4/20 and Chronic Relief is the answer.
In the spirit of legendary fundraisers like the Jerry Lewis MDA Labor Day Telethon, Chronic Relief looks to bring many of the same aspects of the time-honored tradition, but in a virtual world where viewers can join a live-stream. The event will act as a platform to raise money for charity with 100% of all funds raised via donation during broadcast will be given to Feeding America (501c3). A donation link will be visible on the live-stream screen. In addition to the opportunity to donate to feedingamerica.org, viewers can expect to see video segments from artists, influencers and celebrities. Live musical performances and interviews with influencers will stream live from our Seattle-based studio in a true variety-show format. It will be a 4/20 to remember.”
The CEO of Hollister Biosciences Inc, Carl Saling, shared: “We are honored to be part of Chronic Relief 4/20. So many families are struggling right now and we all must step up and do our part to help. Hollister Cannabis Co has been making and donating hand sanitizer all over the community. This event is an opportunity to come together and really do some good.”
Chronic Relief 4/20 is taking place on Monday, 4/20/20 from 12-5PM PST. For more information and to RSVP for this remarkable live-stream fundraiser, please visit farechild.com.
The Team Behind Chronic Relief
Farechild Events is the premier event production platform focusing on the cannabis industry.
Feeding America is a not for profit. As the COVID-19 pandemic continues, we are committed to serving communities and individuals facing hunger across America, wherever they are. Every dollar raised from the COVID-19 response fund will be used to get food and funds to local food banks across the US. You can help make sure we can be there for our neighbors in need during this time of uncertainty. www.feedingamerica.org
Atomic Studios is our broadcast studio partner and is located in Seattle’s South Lake Union. The studio is designed for live stream productions and includes cameras, lighting, graphics, audio, replay, and the best team in the Pacific Northwest to make it happen. www.atomicinfotech.com
Wick & Mortar is the award-winning cannabis-focused branding and content marketing agency. Their core services include branding, strategy, copywriting, packaging design, packaging production, and website design. Additional services include marketing consulting, photography, videography, and advertising. For over 10 years, Wick & Mortar has brought a plethora of experience, deep-rooted relationships and polished presentation to some of the most recognized projects in the cannabis industry. www.wickandmortar.com
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.
Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com
Tags: Cannabis, CBD, CSE, Hemp, Marijuana Posted in Hollister Biosciences | Comments Off on Hollister Biosciences Inc.$HOLL.ca Division Hollister #Cannabis Co Becomes Official Brand Partner for Chronic Relief 4/20 Fundraiser in Support of Feeding America $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 3:55 PM on Wednesday, April 15th, 2020
SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More
With greater acceptance and understanding, people know more than ever about CBD. But did you know these five fascinating facts?
As research continues to grow, so too does the demand for CBD products
So much so, in fact, that the market has yielded some impressive profits in the two years since the Farm Bill was passed; which effectively legalised hemp and CBD at the federal level
With all the hype surrounding CBD, there’s plenty of information to be had on the compound. Derived from hemp, CBD is one of 113 cannabinoids found in cannabis. Each cannabinoid interacts with our body in a specific way, and we even have specialised receptors in our nervous system to accept them.
As research continues to grow, so too does the demand for CBD products. So much so, in fact, that the market has yielded some impressive profits in the two years since the Farm Bill was passed; which effectively legalised hemp and CBD at the federal level.
Whatever you might know about CBD, there’s a good chance you don’t know these five facts. Keep reading to learn what they are, they might just surprise you.
1. It’s One Of The Fastest-Growing Industries In History: You can buy pharmaceutical grade CBD oil in stores and at several online providers all over the country. This massive spread of CBD products is due to the incredible demand for CBD and CBD-based products; causing the industry to become one of the fastest-growing in history.
Financial experts have predicted that the CBD industry has grown at around 107% per-year, and will continue to do so for the better half of the decade. People simply love CBD products, and as researchers discover more amazing benefits, the demand only grows.
The CBD industry managed to surpass the one billion dollar mark last year, and is projected to surpass 10-20 billion in the next few years. As misinformation and stigma dissipate, facts and scientific data take their place, making cannabis, hemp, and CBD better understood by everyone.
2. It Can Help Cancer Patients Manage Symptoms: CBD offers some very promising results in cancer patients. Cancer is a devastating condition where cells divide uncontrollably and destroy tissue. This can include muscle tissue, organs, blood vessels, and more. Often, cancer is incredibly painful, and the treatments available for cancer are no less uncomfortable than the disease itself.
Cannabinoids may actually help with more than just the symptoms of cancer, however. Certain studies have shown that cannabinoids, including CBD, might actually help to slow the growth of tumours. Another study found that it could potentially make cancerous cells more susceptible to radiation while not affecting healthy cells.
Overall, it would seem that CBD has the ability to inhibit cancer growth, manage symptoms, and aid in the destruction of cancerous cells. These are all great things, but further research must be conducted before these benefits can be cemented into CBD’s repertoire.
3. There’s a CBD-Based Drug Available for Seizures: Believe it or not, the FDA itself has recognised and performed research on the effectiveness of CBD in treating certain conditions, and recently approved a drug called Epidiolex, which is formulated from CBD. This breakthrough in CBD research proves that CBD is both useful and effective in medical applications.
Epidiolex is used to treat certain severe forms of epilepsy, such as Dravet Syndrome. These rare conditions can cause debilitating and often dangerous seizures. The CBD-based drug seems to reduce the number of as well as the severity of these seizures, making life more comfortable and manageable for those suffering from these conditions.
4. CBD Is Opening New Doors In Medical Research: Besides treating epilepsy and cancer, CBD is opening doors to all kinds of new research. Studies have been conducted on the compound’s effectiveness at treating or affecting conditions such as anxiety; depression; PTSD; diabetes; heart disease; high blood pressure; skin conditions; Alzheimer’s and more.
According to the Penguin CBD team, now that CBD and hemp are officially legalised, there’s plenty of room for more research and plenty of money in the industry to support new studies. With specialised receptors for cannabinoids in our nervous systems, it’s clear that our bodies are somewhat designed to accept and make use of cannabinoids, and their incredible list of benefits only continues to grow as we learn more.
CBD has yet another useful application: helping to treat addiction. Opioid-based painkillers are the cause of thousands of overdoses and deaths each year, and yet, they’re continuously prescribed without any valid alternatives available. CBD is effective at pain management but has also been shown to reduce the symptoms of withdrawal and help reduce cravings in addicts.
5. CBD Can Be Used In Pets And Children: You probably didn’t know you could give your furry friend CBD, did you? CBD pet treats are available for pets who suffer from chronic pain, inflammation, anxiety, or even have appetite problems. They’re tasty and you’re pet won’t know that they contain anything other than that yummy steak flavour they love so much!
Pet owners all over the country are choosing CBD oil to bring their pets easy comfort and relief from conditions like arthritis. While the research on pets and CBD is scarce, millions of pet owners swear by CBD and its effectiveness.
You can also give CBD to your children. In fact, there are studies available that suggest CBD may be an effective treatment for ADHD instead of giving stimulants to your child. That’s not to say you should immediately replace your child’s ADHD medication with CBD, but you can certainly talk with your child’s doctor about this natural alternative. Many parents have found CBD to be effective at managing hyperactive children and those with focus or concentration issues.
Children also suffer from chronic pain, inflammation, and conditions such as anxiety. CBD is truly an amazing compound with a myriad of useful applications, and it spans beyond just use in adults and humans. Your pets and your children can experience its benefits as well.
CBD is only growing in popularity, and you can be sure to see some more amazing benefits discovered as more money and effort go into CBD studies. With CBD’s legal status solidified, it’s not much easier to study its effects and perform clinical trials without the threat of government interference. Where will the future of CBD and CBD products will take us? The road ahead is set to be an exciting one…
Tags: Cannabis, CBD, CSE, Hemp, Marijuana Posted in Hollister Biosciences | Comments Off on With greater acceptance and understanding, people know more than ever about #CBD – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
Posted by AGORACOM-JC
at 6:51 AM on Tuesday, April 14th, 2020
Shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company
DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies
VANCOUVER, April 14, 2020 –Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“), is pleased to announce that its shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (“DTC“). DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded companies. DTC services provide cost benefits for investors and brokers trading Canadian securities in the United States.
About Hollister Biosciences Inc.
Hollister Biosciences Inc. is a diversified cannabis company with multiple, high-quality products now carried in 220 of Indus Holdings (CSE: INDS), Hollister’s exclusive distribution partner’s 600 dispensaries. This level of penetration is expected to grow as the Company accelerates its seed to shelf, high margin business and product development model.
Capitalizing on this success, Hollister’s vision is to become the sought-after premium brand portfolio of innovative, high quality cannabis across multiple states and hemp products nationwide.
Our wholly owned California subsidiary, Hollister Cannabis Co, is the 1st state and locally licensed Cannabis Company in the City of Hollister, California, the birthplace of the “American Biker” from which we embrace the outlaw roots of Hollister to drive our Company fearlessly down the road of success.
Products from Hollister Cannabis Co. include HashBone, the brand’s premier artisanal hash-infused pre-roll ranked as California’s #1 hash infused pre-roll, along with solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com
Tags: Cannabis, CBD, CSE, Hemp Posted in Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca Announces DTC Eligibility $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca
View original content to download multimedia:
View original content to download multimedia:
